GlassScriptPhysician profile
Nicole Lee
NPI 1740287036
$456.85
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $18.35 · 2021: $25.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $260.61 | 2019 | |
| Pfizer INC. | $42.68 | 2019-2020 | |
| Amgen INC. | $32.85 | 2019 | |
| Seagen INC. | $32.72 | 2019 | |
| Abbvie INC. | $23.64 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.48 | 2019 | |
| Rigel Pharmaceuticals, INC. | $15.33 | 2019 | |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Clovis Oncology, INC. | $7.69 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.